Security record · archived quarter
TERN
Terns Pharmaceuticals, Inc. · Healthcare · Biotechnology
11Tracked holders
—Δ holders
7.84MShares held
$53.39MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 105 | +14 | 70.88M | $3.72B | +22 | −9 |
| Q4 2025 | 91 | +4 | 71.76M | $2.90B | +5 | — |
| Q3 2025 | 16 | 0 | 30.56M | $229.52M | — | — |
| Q2 2025 | 13 | 0 | 20.60M | $76.83M | +2 | −2 |
| Q1 2025 | 10 | -3 | 10.19M | $28.12M | — | −3 |
| Q4 2024 | 13 | +2 | 13.10M | $72.60M | +2 | — |
| Q3 2024 | 10 | -1 | 11.63M | $97.00M | — | −1 |
| Q2 2024 | 11 | — | 7.84M | $53.39M | — | — |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 2.69M | — | $18.32M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.46M | — | $9.94M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 1.14M | — | $7.77M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.12M | — | $7.64M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.12M | — | $7.64M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 975.00K | — | $6.64M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 224.18K | — | $1.53M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 224.18K | — | $1.53M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 224.18K | — | $1.53M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 224.18K | — | $1.53M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 87.50K | — | $595,875 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 61.42K | — | $418,291 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 26.96K | — | $183,632 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 26.68K | — | $182,000 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 25.98K | — | $176,958 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 314 holders, 121.84M shares, $6.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API